Gene Delivery: Looking Past the Skeptics
This article was originally published in Start Up
Executive Summary
The criticism of gene therapy has been continual and consistent. But in fact, at least some delivery systems do work. It is true, however, that not all vectors work in all diseases, and the challenge for gene delivery start-ups is figuring out which ones work where.
You may also be interested in...
Austrianova FSG Biotechnologie GMBH
Austrianova is pursuing both cell- and retroviral gene-therapy technologies to treat cancer. The Vienna-based company's most advanced project is a cell-therapy designed to treat pancreatic cancer which has gained Orphan Drug status in Europe.
Cardiac Gene Therapy: Combination Products' Next Frontier?
Orthopedic biomaterials and drug-eluting stents are only the first hint at the potentially transforming nature of combination products: device/biologic combination products that may bring a revolution to clinical therapy and to the device industry. In vascular medicine, catheter-based delivery of cardiac gene therapy may become a significant advance, yet with scant clinical evidence of efficacy and only anecdotal physician experience using catheter delivery systems, the field remains all promise. Many device executives think they see a path emerging, largely due to fundamental changes in the dynamics of their industry that are moving device business models closer to that of their pharma industry cousins.
Cardiac Gene Therapy: Combination Products' Next Frontier?
Orthopedic biomaterials and drug-eluting stents are only the first hint at the potentially transforming nature of combination products: device/biologic combination products that may bring a revolution to clinical therapy and to the device industry. In vascular medicine, catheter-based delivery of cardiac gene therapy may become a significant advance, yet with scant clinical evidence of efficacy and only anecdotal physician experience using catheter delivery systems, the field remains all promise. Many device executives think they see a path emerging, largely due to fundamental changes in the dynamics of their industry that are moving device business models closer to that of their pharma industry cousins.